Abstract 209P
Background
Patients (pts) with lung cancer had high rates of brain metastasis (BM). Genetic alterations were associated with the metastatic spread of lung cancer cells in recent study, lung cancer driver genes, such as EGFR, ALK, and RET are risk factors for brain metastasis in advanced lung cancer pts. The number of CNV regions was markedly higher in the secondary metastatic tumor than the primary tumor in the lung. However, the precise mechanisms in BM were still unclear. In this study, we explored the clinical and molecular features of lung cancer with brain metastases in Chinese real word.
Methods
This study retrospectively analyzed the genomic alteration of Chinese lung cancer with brain metastases pts during 2019-2022. Next-generation sequencing (NGS) was performed to detect gene mutations in tumor. Lung cancer driver genes set, as EGFR, ALK, ROS1, BRAF, ERBB2, MET, KRAS and RET were evaluated in those pts.
Results
193 lung cancer with brain metastases pts were enrolled. Male:Female ratio: 128:65. Median age 61 years(Min-Max: 38-78). 79% of pts had CNV, and tumors with CNV had higher TMB values than those without CNV (7.7 vs. 2.8, p<0.001). The top3 amplification genes were: EGFR(n=25), MYC(n=11), ERBB2(n=10), and the three most frequently deletion genes were: CDKN2A (n=69), CDKN2B (n=69), PTEN (n=15). Among pts with TMB≥10, the proportion of pts with CNV was higher than that of pts without CNV (24% vs. 5%, χ2=7.22, p < 0.05). The numbers of pts with driver gene mutation and pts without driver gene mutation were 145 and 48, respectively, and there was no significant difference in age between the two groups. Pts with CNV and no driver gene mutation had higher TMB values (average TMB=9.6). The proportion of pts that carrying CNV in driver gene mutation tumors was similar to those without driver gene mutation (82% vs. 68%).
Conclusions
79% of pts with brain metastases had CNV. The top3 amplification genes were: EGFR, MYC, ERBB2, and the three most frequently deletion genes were: CDKN2A, CDKN2B, PTEN. The proportion of pts that carrying CNV in driver gene mutation tumors was similar to those without driver gene mutation. Pts with CNV and no driver gene mutation had higher TMB values, indicating the pts may have more clinical benefits from immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xianfeng Zhang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
165P - Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response (pCR) in HER2-positive early breast cancer (EBC): A sub analysis of PHERGain trial
Presenter: Maria Gion Cortes
Session: Poster session 01
166P - Metabolomic prediction of breast cancer treatment toxicities
Presenter: Max Piffoux
Session: Poster session 01
167P - A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Preliminary results from MIRACLE trial
Presenter: Tan Yujing
Session: Poster session 01
168P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: SHRUTI KAHOL
Session: Poster session 01
169P - Integration of metabolomics and transcriptomics to reveal potential biomarkers associated with treatment response of neoadjuvant therapy in HER2+ breast cancer
Presenter: Ningning Zhang
Session: Poster session 01
170P - Clinical significance and functional role of GPR56 (ADGRG1) in breast cancer
Presenter: Haizhu Chen
Session: Poster session 01
172P - T cell-derived circulating DNA and tumour inflammatory microenvironment in EGFR-mutant advanced non-small cell lung cancer: Correlation with the outcome of EGFR TKI treatment
Presenter: Nicha Zungsontiporn
Session: Poster session 01
173P - Expression of programmed death-ligand 1 and EGFR on circulating tumour cells in advanced lung cancer patients
Presenter: Jayant Khandare
Session: Poster session 01
174P - Frequency and prognostic value of circulating tumor cells in cancer of unknown primary
Presenter: Maria Pouyiourou
Session: Poster session 01